|
1
|
Stupp R, Mason WP, van den Bent MJ, et al:
European Organisation for Research and Treatment of Cancer Brain
Tumor and Radiotherapy Groups; National Cancer Institute of Canada
Clinical Trials Group: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burnet NG, Jefferies SJ, Benson RJ, et al:
Years of life lost (YLL) from cancer is an important measure of
population burden – and should be considered when allocating
research funds. Br J Cancer. 92:241–245. 2005.PubMed/NCBI
|
|
3
|
Leibetseder A, Ackerl M, Flechl B, et al:
Outcome and molecular characteristics of adolescent and young adult
patients with newly diagnosed primary glioblastoma: a study of the
Society of Austrian Neurooncology (SANO). Neuro Oncol. 15:112–121.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kinsella TJ, Collins J, Rowland J, et al:
Pharmacology and phase I/II study of continuous intravenous
infusions of iododeoxyuridine and hyperfractionated radiotherapy in
patients with glioblastoma multiforme. J Clin Oncol. 6:871–879.
1988.PubMed/NCBI
|
|
5
|
Hammoud MA, Sawaya R, Shi W, Thall PF and
Leeds NE: Prognostic significance of preoperative MRI scans in
glioblastoma multiforme. J Neurooncol. 27:65–73. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gulati S, Jakola AS, Nerland US, Weber C
and Solheim O: The risk of getting worse: surgically acquired
deficits, perioperative complications, and functional outcomes
after primary resection of glioblastoma. World Neurosurg.
76:572–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedman HS, Kerby T and Calvert H:
Temozolomide and treatment of malignant glioma. Clin Cancer Res.
6:2585–2597. 2000.PubMed/NCBI
|
|
8
|
Roos WP and Kaina B: DNA damage-induced
apoptosis: from specific DNA lesions to the DNA damage response and
apoptosis. Cancer Lett. 332:237–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esteller M, Hamilton SR, Burger PC, et al:
Inactivation of the DNA repair gene O6-methylguanine-DNA
methyltransferase by promoter hypermethylation is a common event in
primary human neoplasia. Cancer Res. 59:793–797. 1999.PubMed/NCBI
|
|
10
|
Felsberg J, Thon N, Eigenbrod S, et al:
German Glioma Network: Promoter methylation and expression of MGMT
and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in
paired primary and recurrent glioblastomas. Int J Cancer.
129:659–670. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esteller M: Epigenetic lesions causing
genetic lesions in human cancer: promoter hypermethylation of DNA
repair genes. Eur J Cancer. 36:2294–2300. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esteller M: CpG island hypermethylation
and tumor suppressor genes: a booming present, a brighter future.
Oncogene. 21:5427–5440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reifenberger G, Hentschel B, Felsberg J,
et al: German Glioma Network: Predictive impact of MGMT promoter
methylation in glioblastoma of the elderly. Int J Cancer.
131:1342–1350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stummer W, Nestler U, Stockhammer F, et
al: Favorable outcome in the elderly cohort treated by concomitant
temozolomide radiochemotherapy in a multicentric phase II safety
study of 5-ALA. J Neurooncol. 103:361–370. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Verhaak RG, Hoadley KA, Purdom E, et al:
Cancer Genome Atlas Research Network: Integrated genomic analysis
identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brennan CW, Verhaak RG, McKenna A, et al:
TCGA Research Network: The somatic genomic landscape of
glioblastoma. Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McDonald KL, Rapkins RW, Olivier J, et al:
The T genotype of the MGMT C>T (rs16906252) enhancer
single-nucleotide polymorphism (SNP) is associated with promoter
methylation and longer survival in glioblastoma patients. Eur J
Cancer. 49:360–368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jeuken J, Sijben A, Alenda C, et al:
Robust detection of EGFR copy number changes and EGFR variant III:
technical aspects and relevance for glioma diagnostics. Brain
Pathol. 19:661–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tabone T, Abuhusain HJ, Nowak AK, et al:
Multigene profiling to identify alternative treatment options for
glioblastoma: a pilot study. J Clin Pathol. 67:550–555. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Esteller M, Garcia-Foncillas J, Andion E,
et al: Inactivation of the DNA-repair gene MGMT and the clinical
response of gliomas to alkylating agents. N Engl J Med.
343:1350–1354. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hegi ME, Diserens AC, Godard S, et al:
Clinical trial substantiates the predictive value of
O-6-methylguanine-DNA methyltransferase promoter methylation in
glioblastoma patients treated with temozolomide. Clin Cancer Res.
10:1871–1874. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pegg AE: Mammalian O6-alkylguanine-DNA
alkyltransferase: regulation and importance in response to
alkylating carcinogenic and therapeutic agents. Cancer Res.
50:6119–6129. 1990.PubMed/NCBI
|
|
25
|
Christians A, Hartmann C, Benner A, et al:
Prognostic value of three different methods of MGMT promoter
methylation analysis in a prospective trial on newly diagnosed
glioblastoma. PloS one. 7:e334492012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karayan-Tapon L, Quillien V, Guilhot J, et
al: Prognostic value of O6-methylguanine-DNA methyltransferase
status in glioblastoma patients, assessed by five different
methods. J Neurooncol. 97:311–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rosty C, Young JP, Walsh MD, et al: PIK3CA
activating mutation in colorectal carcinoma: associations with
molecular features and survival. PLoS One. 8:e654792013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen L, Kondo Y, Rosner GL, et al: MGMT
promoter methylation and field defect in sporadic colorectal
cancer. J Natl Cancer Inst. 97:1330–1338. 2005. View Article : Google Scholar : PubMed/NCBI
|
